multiple sclerosis (ms) is an inflammatory disease of central nervous system (cns) and sexual dysfunction (sd) is one of the most common disabilities of ms women. the aim of this study was to determine sexual function of women with ms (multiple sclerosis). one hundred definite ms patients ms patients and fifty age-matched healthy controls were enrolled. demographic data (sex, age), duration of ...

BACKGROUND Clinical trials established the efficacy and safety of natalizumab. Data are needed over longer periods of time and in the clinical practice setting. OBJECTIVE To evaluate long-term safety of natalizumab and its impact on annualised relapse rate and Expanded Disability Status Scale (EDSS) progression in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS The Tysa...

background: multiple sclerosis (ms) is a neurological disease with a variety of signs and symptoms. exercise therapy has been shown to improve physical functions in ms. however, questions about an optimal exercise therapy remain. in this regard, we suggest a combined exercise therapy including aerobic and resistance exercises for ms patients. the study is designed to observe, test and compare t...

[Purpose] To investigate the relationship between isokinetic knee muscle strength and kinematic, kinetic and spatiotemporal gait parameters of patients with multiple sclerosis (MS). [Subjects and Methods] Twenty-nine MS patients (mean age 31.5±6.5) were investigated in this study. The isokinetic knee muscle strength and gait parameters of MS patients with moderate and severe disability, as dete...

Progressive myelopathies can be secondary to inborn errors of metabolism (IEM) such as mucopolysaccharidosis, mucolipidosis, and adrenomyeloneuropathy. The available scale, Japanese Orthopaedic Association (JOA) score, was validated only for degenerative vertebral diseases. Our objective is to propose and validate a new scale addressing progressive myelopathies and to present validating data fo...

Background/Aim. The aim of this study is to examine the effects of perceived cognitive dysfunction and of depression, on self-reported QoL, in a Greek population sample of MS patients. Methods. One hundred outpatients diagnosed with MS completed the Short-Form-36 Health Survey (SF-36), as well as the Perceived Deficits Questionnaire (PDQ) and the Depression subscale of the Mental Health Invento...

INTRODUCTION. In multiple sclerosis (MS), patient disability is assessed according to the qualitative, ordinal Expanded Disability Status Scale (EDSS). In order to monitor treatment efficacy and disease progression, quantitative MRI metrics are sought that will correlate with EDSS [1]. In the relapsing-remitting MS (RRMS) literature, r-values for correlation with EDSS of various metrics have ra...

Accurate, efficient measurement of disease status has become a key issue in MS clinical practice and research. Despite some perceived problems, the Expanded Disability Status Scale (EDSS) remains the most widely used comprehensive measure of impairment. There is also a place for more restricted scales of impairment which focus on some aspects of neurological function in more detail than the EDS...

OBJECTIVE To characterize effects of alemtuzumab treatment on measures of disability improvement in patients with relapsing-remitting multiple sclerosis (RRMS) with inadequate response (≥1 relapse) to prior therapy. METHODS Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) II, a 2-year randomized, rater-blinded, active-controlled, head-to-head, phase 3 trial, compar...

Tecfidera has been shown to be of benefit in relapsing multiple sclerosis in two Phase III clinical trials. In the DEFINE trial, the medication produced a 49% reduction in the proportion of people who experienced relapses over 2 years, and had a similar significant impact on disease activity detected on MRI., This resulted in a 38% reduction in the risk of confirmed progression of disability as...